% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Feb 7, 2012 4:53 PM Flag

    VRTX's all-oral best guesses

    TVR is one of the best PI even compared to other PIs under development. VX-222 is the best non-nuc polymerase inhibitor.

    BMY has an excellent NS5A inhibitor. Yet when it is combined with their PI, the combo can achieve an SVR rate of only 2 out of 9 (22%) hcv gt 1a infected patients after dosing 24 weeks (NEJM just published). Most all-oral drugs have difficulty with difficult-to-treat patients.

    Oral drugs have a large relapse rate. They have to be tested for UND 24 or 48 weeks following the end of dosing. There are only two or three drug combos which have SVR24 data. It is difficult to predict what the outcome will be for any all-oral drugs because of dearth of data.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
79.71-2.02(-2.47%)Feb 11 3:59 PMEST